Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 3, 2004, Pages 186-194

  Avivi, Irit ^a,e   Chakrabarti, Suparno ^b,c   Milligan, Donald W ^b   Waldmann, H ^d   Hale, Geoff ^d   Osman, Husam ^b   Ward, Katherine N ^a   Fegan, Christopher D ^b   Yong, Kwee ^a   Goldstone, Anthony H ^a   Linch, David C ^a   MacKinnon, Stephen ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adenovirus; Alemtuzumab; Lymphocyte recovery; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOVIRUS; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; INCIDENCE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; VIROLOGY; VIRUS INFECTION; VIRUS REACTIVATION;

ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 10744228219     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.11.001     Document Type: Article

References (26)

1. Shields A.F. Hackman R.C. Fife K.H. et al. Adenovirus infections in patients undergoing bone marrow transplantation N Engl J Med. 312 1985 529-533
2. Flomenberg P. Babbitt J. Drobyski W.R. et al. Increased incidence of adenovirus disease in bone marrow transplant recipients J Infect Dis. 169 1994 775-781
3. Blanke C. Clark C. Broun R. et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections Am J Med. 99 1995 326-328
4. Childs R. Sanchez C. Engler H. et al. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine Bone Marrow Transplant. 22 1998 889-893
5. La Rosa A.M. Champlin R.E. Mirza N. et al. Adenovirus infections in adult recipients of blood and marrow transplants Clin Infect Dis. 32 2001 871-876
6. Howard D.S. Phillips II G.L. Reece D.E. et al. Adenovirus infections in hematopoietic stem cell transplant recipients Clin Infect Dis. 29 1999 1494-1501
7. Baldwin A. Kingman H. Darville M. et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation Bone Marrow Transplant. 26 2000 1333-1338
8. Hale G.A. Heslop H.E. Krance R.A. et al. Adenovirus infection after pediatric bone marrow transplantation Bone Marrow Transplant. 23 1999 277-282
9. Chakrabarti S. Mautner V. Osman H. et al. Adenovirus infections following allogeneic stem cell transplantation: the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery Blood. 100 2002 1619-1627
10. Chakrabarti S. Mackinnon S. Chopra R. et al. High incidence of CMV infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution Blood. 99 2002 4357-4363
11. Chakrabarti S. Avivi I. Mackinnon S. et al. Respiratory virus infections in transplant recipients after reduced intensity conditioning with Campath-1H: high incidence but low mortality Br J Haematol. 119 2002 1125-1132
12. McSweeney P.A. Niederwieser D. Shizuru J.A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood. 97 2001 3390-3400
13. Slavin S. Nagler A. Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood. 91 1998 756-763
14. Giralt S. Thall P.F. Khouri I. et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood. 97 2001 631-637
15. Barrett J. Childs R. Non-myeloablative stem cell transplants Br J Haematol. 11 2000 6-17
16. Chakraverty R. Peggs K. Chopra R. et al. Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen Blood. 99 2001 1071-1078
17. Junghanss C. Boeckh M. Carter R.A. et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood. 99 2002 1978-1985
18. Mohty M. Faucher C. Vey N. et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation Bone Marrow Transplant. 26 2000 251-255
19. Li C.R. Greenberg P.D. Gilbert M.J. Goodrich J.M. Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood. 83 1994 1971-1979
20. Lankester A. Heemskerk B. Vossen T. et al. Adenovirus infections in pediatric stem cell transplant recipients: feasibility of adoptive cellular immunotherapy Bone Marrow Transplant. 31suppl 1 2003 S11
21. Chakrabarti S. Collingham K.E. Fegan C. Milligan D.W. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy Bone Marrow Transplant. 23 1999 1209-1211
22. Hammer S.M. Inouye R.T. Antiviral agents In: Richman D.D. Whitley R.J. Hayden F.G. (Eds.), Clinical Virology 1997 185-232 Churchill-Livingstone New York
23. Bruno B. Gooley T. Hackman R.C. et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival Biol Blood Marrow Transplant. 9 2003 341-352
24. Chakrabarti S. Pillay D. Ratcliffe D. et al. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance J Infect Dis. 181 2000 2055-2058
25. Prentice H.G. Gluckman E. Powles R.L. et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group Bone Marrow Transplant. 19 1997 129-133
26. Lion T. Baumgartinger R. Watzinger F. et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease Blood. 102 2003 1114-1120